How Wegovy BMI Requirements Work for UK Patients
Understanding Wegovy BMI Eligibility for Prescription Weight Loss
Wegovy BMI requirements are clearly defined by the MHRA for prescription weight loss treatment in the UK. This prescription-only medicine is licensed for adults with a body mass index of 30 or above, or those with a BMI of 27 or higher who have weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnoea. The BMI thresholds ensure Wegovy is prescribed to patients who will benefit most from this advanced weight management treatment.
Unlike over-the-counter weight loss products, Wegovy BMI criteria reflect the medicine's classification as a prescription-only treatment requiring clinical oversight. Our prescribers at EverydayMeds assess each patient's BMI alongside their medical history during the clinical assessment process. This ensures Wegovy is prescribed safely and appropriately, maximising the potential for successful weight management outcomes whilst minimising risks.
Wegovy BMI Pricing and Treatment Investment
Understanding Wegovy BMI treatment costs helps patients plan their weight loss journey effectively. Our starter dose of 0.25mg costs £79.99 with discount code FIRST40 applied at checkout for new customers. The treatment follows a structured dose escalation: 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance dose of 2.4mg at £209.99. Returning customers benefit from discount code DOSE25 at checkout.
For patients meeting Wegovy BMI requirements who want treatment continuity, our bundles provide convenient multi-month supplies. The Intro Trio bundle (0.25mg, 0.5mg, 1mg) costs £299.99, covering the first 12 weeks of treatment. Our Ultimate Stability Trio provides three months of maintenance 2.4mg doses for £649.99, ensuring uninterrupted treatment for patients who've reached their target dose after meeting Wegovy BMI criteria.
Clinical Evidence Supporting Wegovy BMI Treatment Efficacy
The STEP clinical trials provide compelling evidence for Wegovy's effectiveness in patients meeting BMI criteria. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. These results demonstrate why Wegovy BMI requirements exist - to identify patients most likely to achieve meaningful weight loss.
Long-term sustainability data from STEP 5 showed patients maintained approximately clinically studied weight loss at two years, proving Wegovy BMI treatment delivers lasting results. The recent SELECT trial revealed an additional benefit: a 20% reduction in major cardiovascular events, making Wegovy BMI treatment valuable beyond weight loss for eligible patients with existing heart disease.
How Wegovy Works for BMI-Eligible Patients
Wegovy's mechanism of action makes it particularly effective for patients meeting BMI criteria for prescription weight loss. As a GLP-1 receptor agonist, semaglutide mimics a natural hormone that regulates appetite and blood sugar levels. This once-weekly injection works on the brain's appetite centres, reducing hunger signals and promoting feelings of fullness after smaller meals. Many patients report decreased food cravings and a natural reduction in portion sizes, supporting sustainable weight loss habits. The medicine's prolonged action means patients maintain appetite control throughout the week, making it easier to adhere to reduced-calorie diets essential for weight management success.
Ordering Wegovy BMI Treatment Through EverydayMeds
Accessing Wegovy BMI treatment begins with our streamlined 3-minute online clinical assessment, designed to verify eligibility and ensure safe prescribing. Our questionnaire covers your BMI calculation, medical history, current medications, and weight loss goals to provide prescribers with comprehensive information for decision-making. Once submitted, our qualified prescribers review your assessment - standard review takes 3 working days, or choose express 24-hour review for faster processing. Upon approval, your Wegovy is dispatched via next-day delivery using temperature-controlled packaging to maintain the medicine's efficacy. Our GPhC-registered pharmacy #9012878 ensures all treatments are genuine Novo Nordisk products stored to pharmaceutical standards.
Wegovy BMI Storage and Practical Considerations
Proper storage is crucial for maintaining Wegovy's effectiveness throughout your BMI-targeted weight loss treatment. Store unused pens in the fridge at 2-8°C, though Wegovy offers excellent travel flexibility with up to 6 weeks storage at room temperature below 30°C once removed from refrigeration. The FlexTouch pen design makes weekly injections straightforward, with clear dosing windows and simple injection technique. Dose escalation is mandatory regardless of your starting BMI - all patients begin with 0.25mg and increase monthly until reaching the 2.4mg maintenance dose. This gradual increase minimises side effects whilst allowing your body to adjust to the medicine's appetite-suppressing effects.
Wegovy BMI Success Factors and Long-term Commitment
Achieving optimal results from Wegovy BMI treatment requires understanding that this prescription-only medicine works best as part of comprehensive lifestyle changes. Clinical trials demonstrated that patients who combined Wegovy with reduced-calorie diets and increased physical activity achieved the most significant weight loss outcomes. The medicine's appetite-suppressing effects make dietary changes more manageable, whilst improved energy levels often support increased physical activity.
Long-term commitment is essential for Wegovy BMI treatment success, as STEP trial extensions showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. This highlights that weight management is an ongoing process rather than a temporary intervention. Patients who view Wegovy as a long-term tool for maintaining healthy BMI levels, combined with sustained lifestyle modifications, achieve the best outcomes for lasting weight management success.
Start Your Wegovy BMI Treatment Journey Today
Ready to begin your prescription weight loss journey with Wegovy BMI treatment? Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and take the first step towards clinically-proven weight management. Use discount code FIRST40 at checkout if you're a new customer, or DOSE25 for returning patients to access our competitive pricing. Our expert clinical team reviews every assessment to ensure safe, appropriate prescribing tailored to your individual BMI and health profile. With next-day delivery and ongoing support from our GPhC-registered pharmacy #9012878, starting your Wegovy treatment has never been more convenient. Don't wait - begin your transformation with the UK's most effective prescription weight loss treatment available through EverydayMeds today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
